Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer

Novel therapeutic approaches against ovarian cancer (OC) are urgently needed because of its high rate of recurrence even after extensive surgery and multi-agent chemotherapy. We aimed to develop a novel anti-CD24 chimeric antigen receptor (CAR) as an immunotherapeutic approach against OC cells and cancer stem cells (CSC). CSC represents a subpopulation of the tumor characterized by enhanced chemoresistance as well as the increased capability of self-renewal and metastasis. We designed a codon-optimized third-generation CAR containing the highly active single chain variable fragment (scFv) “SWA11” against CD24. We equipped the human NK-cell line NK-92 with the anti-CD24 CAR and an anti-CD19 control CAR using lentiviral transduction. Engineered NK-92 cells showed high cytotoxic activity against CD24-positive OC cell lines (SKOV3, OVCAR3). This effect was restricted to CD24-expressing cells as shown after lentiviral transduction of CD24-negative cell lines (A2780, HEK-293T) with CD24 transmembrane proteins. Additionally, NK-92 cells equipped with our novel anti-CD24 CAR were highly effective against patient-derived primary ovarian cancer cells. The activation of NK cells was shown by specific IFNγ secretion upon antigen stimulation. To further reduce possible off-target effects in vivo, we applied a dual-CAR approach using an anti-CD24-CD28-41BB fusion protein linked via a 2A sequence to an anti-mesothelin-CD3ζ-CAR. The dual-CAR was simultaneously active against CD24 and mesothelin expressing cells. Our novel anti-CD24-CAR showed a highly cytotoxic effect against OC cell lines and primary OC cells and will be evaluated in future in vivo trials as a promising immunotherapeutic approach against OC.

[1]  D. Torigian,et al.  Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. , 2018, Gastroenterology.

[2]  M. Cui,et al.  Are ovarian cancer stem cells the target for innovative immunotherapy? , 2018, OncoTargets and therapy.

[3]  H. P. Deka Boruah,et al.  Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review , 2018, Experimental cell research.

[4]  A. Schambach,et al.  Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy. , 2017, Human gene therapy.

[5]  Yangbing Zhao,et al.  Increasing the safety and efficacy of chimeric antigen receptor T cell therapy , 2017, Protein & Cell.

[6]  K. Maeda,et al.  CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways , 2017, Oncology reports.

[7]  Yang Wang,et al.  Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design , 2017, Oncotarget.

[8]  I. Scarfò,et al.  Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment , 2017, Journal of Immunotherapy for Cancer.

[9]  H. Klingemann,et al.  Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells , 2016, Front. Immunol..

[10]  Kole T. Roybal,et al.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.

[11]  A. Schambach,et al.  Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors , 2015, Journal of Molecular Medicine.

[12]  B. Vanderhyden,et al.  Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm. , 2014, Reproduction.

[13]  I. Caruana,et al.  From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies. , 2014, Seminars in oncology.

[14]  M. De la Fuente,et al.  Chronic Inflammation and Cytokines in the Tumor Microenvironment , 2014, Journal of immunology research.

[15]  H. Klingemann.  Are natural killer cells superior CAR drivers? , 2014, Oncoimmunology.

[16]  C. Landen,et al.  Ovarian cancer stem cells: are they real and why are they important? , 2014, Gynecologic oncology.

[17]  E. Seifried,et al.  Treatment of patients with advanced cancer with the natural killer cell line NK-92. , 2013, Cytotherapy.

[18]  S. Riddell,et al.  Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells , 2013, Clinical Cancer Research.

[19]  Raphael Sandaltzopoulos,et al.  Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo , 2013, Cancer Immunology Research.

[20]  Michel Sadelain,et al.  The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.

[21]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[22]  T. Schlange,et al.  Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas , 2013, British Journal of Cancer.

[23]  Y. Shin,et al.  CD24⁺ ovary cancer cells exhibit an invasive mesenchymal phenotype. , 2013, Biochemical and biophysical research communications.

[24]  M. Quinn,et al.  Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance , 2013, Journal of cellular biochemistry.

[25]  P. Altevogt,et al.  Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. , 2012, Gastroenterology.

[26]  N. Cho,et al.  Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells. , 2012, Biochemical and biophysical research communications.

[27]  R. Buckanovich,et al.  Ovarian cancer stem cell markers: prognostic and therapeutic implications. , 2012, Cancer letters.

[28]  S. Eccles,et al.  Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling , 2012, Journal of Clinical Immunology.

[29]  G. Coukos,et al.  Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  J. Nesland,et al.  The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells , 2012, BMC Cancer.

[31]  Ronald D. Alvarez,et al.  Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer , 2011, Clinical Cancer Research.

[32]  M. Quinn,et al.  Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell‐like profile , 2011, Journal of cellular biochemistry.

[33]  A. Burges,et al.  Ovarian cancer: diagnosis and treatment. , 2011, Deutsches Arzteblatt international.

[34]  A. Reuss,et al.  Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO , 2010, International Journal of Gynecologic Cancer.

[35]  D. Levine,et al.  Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen , 2010, Clinical Cancer Research.

[36]  P. Zheng,et al.  CD24: from A to Z , 2010, Cellular and Molecular Immunology.

[37]  M. Sadelain,et al.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  W. Wilson,et al.  Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor , 2009, Journal of immunotherapy.

[39]  H. Klingemann,et al.  Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. , 2008, Cytotherapy.

[40]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[41]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  David A. Williams,et al.  Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  J. Sleeman,et al.  CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. , 2005, Cancer research.

[44]  S. Bapat,et al.  Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. , 2005, Cancer research.

[45]  R. Kimmig,et al.  Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. , 2002, European journal of cancer.

[46]  Ying K. Tam,et al.  Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. , 2001, Journal of hematotherapy & stem cell research.

[47]  P. Altevogt,et al.  CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. , 1997, Blood.

[48]  R. Stahel,et al.  CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. , 1992, Cancer research.